Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

WALID L SHAIB

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1831372481
CMS profile
1241130
Location
NEW HAVEN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$14,039.61

84 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $11,437.33 2
Food and Beverage $1,643.42 77
Travel and Lodging $791.88 3
Education $166.98 2

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

WALID L SHAIB

NPI 1831372481 · CMS profile ID 1241130

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

NEW HAVEN, CT

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1831372481?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
WALID L SHAIB, NPI 1831372481, CMS profile ID 1241130. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1831372481?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). WALID L SHAIB, NPI 1831372481, CMS profile ID 1241130. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1831372481?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
WALID L SHAIB, NPI 1831372481, CMS profile ID 1241130, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–84 of 84 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1831372481?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

84 matching records · $14,039.61 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 84 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–84 of 84.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Seagen Inc. $25.0509/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904099501 CMS
E.R. Squibb & Sons, L.L.C. $19.6109/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932821023 CMS
Genentech USA, Inc. $21.9809/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950694053 CMS
TerSera Therapeutics LLC $21.9808/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965170057 CMS
E.R. Squibb & Sons, L.L.C. $17.8508/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932821025 CMS
Janssen Biotech, Inc. $18.7308/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885624027 CMS
Amgen Inc. $19.2108/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939894091 CMS
EISAI INC. $13.1808/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908096839 CMS
TerSera Therapeutics LLC $1,404.0008/19/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943245923 CMS
Bayer HealthCare Pharmaceuticals Inc. $24.3808/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929809821 CMS
E.R. Squibb & Sons, L.L.C. $25.4608/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932821027 CMS
Novartis Pharmaceuticals Corporation $22.5608/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894355777 CMS
GlaxoSmithKline, LLC. $26.9008/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944507229 CMS
Gilead Sciences, Inc. $20.2208/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929539253 CMS
Daiichi Sankyo Inc. $20.5708/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930817935 CMS
TerSera Therapeutics LLC $43.4408/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943245927 CMS
Seagen Inc. $18.3008/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904099479 CMS
Celgene Corporation $17.4308/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932821015 CMS
BeiGene USA, Inc. $18.8607/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940798871 CMS
EISAI INC. $20.6707/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908096853 CMS
Amgen Inc. $18.3307/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939324533 CMS
Regeneron Healthcare Solutions, Inc. $27.7407/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927391304 CMS
TerSera Therapeutics LLC $20.3607/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943245919 CMS
Seagen Inc. $23.5407/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904099493 CMS
Gilead Sciences, Inc. $17.5107/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929539249 CMS
Daiichi Sankyo Inc. $18.3607/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930850847 CMS
PFIZER INC. $16.3607/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949227025 CMS
AstraZeneca Pharmaceuticals LP $21.0007/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915097259 CMS
AstraZeneca Pharmaceuticals LP $15.6406/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914909287 CMS
Karyopharm Therapeutics Inc. $22.3906/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946531645 CMS
Novartis Pharmaceuticals Corporation $17.8806/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894355773 CMS
Janssen Biotech, Inc. $20.8306/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885624043 CMS
PFIZER INC. $16.8806/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949246891 CMS
Lilly USA, LLC $21.3506/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918374285 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $6,339.12 16
PY2020 $8,995.02 10
PY2021 $14.96 1
PY2022 $14,039.61 84
PY2023 $24,409.54 90
PY2024 $32,922.91 147
PY2025 $130,346.29 227

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $757,251.76 35
PY2023 Principal investigator $7,941.75 2
PY2022 Principal investigator $376,337.63 9
PY2021 Principal investigator $293,000.00 3
PY2020 Principal investigator $66,823.55 3
PY2019 Principal investigator $226,121.05 2

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $8,792.20 12/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research
A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy Docetaxel or Pemetrexed in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer NSCLC with EGFR Mutations or Other Genomic Alterations No dispute reported 06/30/2026 1232923262
Principal investigator 1 Merck Sharp & Dohme LLC $4,436.59 12/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers PC
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy KEYNOTE-564 No dispute reported 06/30/2026 1232925961
Principal investigator 1 Merck Sharp & Dohme LLC $18,435.62 12/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers PC
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1232926697
Principal investigator 1 Merck Sharp & Dohme LLC $17,750.98 12/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers PC
A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab No dispute reported 06/30/2026 1232926699
Principal investigator 1 Merck Sharp & Dohme LLC $11,263.62 12/31/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research
A Multicenter, Double-blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 Plus Pembrolizumab MK-3475 Versus Placebo Plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Neph No dispute reported 06/30/2026 1232934940
Principal investigator 1 Exelixis Inc. $338.00 12/23/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382844
Principal investigator 1 Exelixis Inc. $8,088.00 12/23/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382848
Principal investigator 1 Genentech, Inc. $1,336.00 12/19/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211631383
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,425.00 12/17/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS, PC
a phase 3 multi center,open label,sponsor blinded,randomized study of azd0901 monotherapy compared with investigator s choice of therapy in second or later line adult participants with advanced metastatic gastric or gastroesophageal junction adenocarcinoma expressing claudin18 2 No dispute reported 06/30/2026 1185548117
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $34,242.00 12/09/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, PC
Phase 2/3 BMS-986504+Gemcitabine/Abraxane vs Gemcitabine/Abraxane in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) No dispute reported 06/30/2026 1235995205
Principal investigator 1 Exelixis Inc. $3,631.85 12/05/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382846
Principal investigator 1 Genentech, Inc. $4,550.00 12/04/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211631440
Principal investigator 1 Genentech, Inc. $908.00 12/01/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CEN
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211631347
Principal investigator 1 Novartis Pharmaceuticals Corporation $217,137.00 11/25/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS, PC
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190303221
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,765.00 11/21/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS, PC
A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17) No dispute reported 06/30/2026 1185548120
Principal investigator 1 ABBVIE INC. $1,500.00 11/20/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202525054
Principal investigator 1 Exelixis Inc. $4,966.60 11/07/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382842
Principal investigator 1 Exelixis Inc. $338.00 10/02/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382838
Principal investigator 1 Exelixis Inc. $9,078.00 10/02/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382840
Principal investigator 1 Novartis Pharmaceuticals Corporation $31,854.10 10/01/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS, PC
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190300105
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,265.00 09/30/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS, PC
a randomized,phase third study of rilvegostomig in combination with fluoropyrimidine and trastuzumab deruxtecan versus trastuzumab,chemotherapy,and pembrolizumab for the first line treatment of positive gastric cancer No dispute reported 06/30/2026 1185548115
Principal investigator 1 Genentech, Inc. $6,366.00 09/22/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Tiragolumab Tecentriq vs Durvalumab in Unresectable Stage III NSCLC No dispute reported 06/30/2026 1211631437
Principal investigator 1 Exelixis Inc. $2,595.40 09/19/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382836
Principal investigator 1 Exelixis Inc. $2,530.80 09/05/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
A Randomized Open-Label Phase 3 Study of XL092 + Atezolizumab vs Regorafenib in Subjects with Metastatic Colorectal Cancer No dispute reported 06/30/2026 1222382834
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,686.49 08/26/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, PC
Phase 2/3 BMS-986504+Gemcitabine/Abraxane vs Gemcitabine/Abraxane in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) No dispute reported 06/30/2026 1235995207
Principal investigator 1 ABBVIE INC. $18,690.00 08/06/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1202502556
Principal investigator 1 Genentech, Inc. $259.20 08/05/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211631509
Principal investigator 1 Novartis Pharmaceuticals Corporation $240,432.99 07/31/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS, PC
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd Line Chronic Phase - Chronic Myelogenous Leukemia No dispute reported 06/30/2026 1190305017
Principal investigator 1 Genentech, Inc. $2,528.00 07/10/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
T DM1 Atezolizumab in high risk HER2 patients with residual disease No dispute reported 06/30/2026 1211631379
Principal investigator 1 Genentech, Inc. $1,500.00 07/03/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211631501
Principal investigator 1 Genentech, Inc. $3,300.00 07/03/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211631504
Principal investigator 1 Genentech, Inc. $250.00 07/01/2025 Non-covered Recipient Entity
NORTHWEST GEORGIA ONCOLOGY CENTERS PC
PH III open label study atezo vs BSC following adjuvant chemo in stage IB IIIA NSCLC No dispute reported 06/30/2026 1211631513
Principal investigator 1 Eli Lilly and Company $765.00 06/03/2025 Non-covered Recipient Entity
NW GA ONCOLOGY CENTERS PC
A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE IN PATIENTS WITH HIGH RISK, NODE POSITIVE, EARLY STAGE, HORMONE RECEPTOR POSITIVE, HUMAN EPIDERMAL RECEPTOR 2 NEGATIVE, BREAST CANCER No dispute reported 06/30/2026 1187885098
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $50,947.00 02/13/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Center, P.c.
Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) No dispute reported 06/30/2026 1235995217
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $299.32 01/27/2025 Non-covered Recipient Entity
Northwest Georgia Oncology Centers, PC
Randomized, Double-Blind, Multicenter Phase 3 Trial of BMS-986489 (BMS-986012 + nivolumab FDC) in combination with Carboplatin plus Etoposide vs Atezolizumab in combination with Carboplatin plus Etoposide as First-line Therapy in Extensive-Stage Small Cell Lung Cancer (CA245-0001) No dispute reported 06/30/2026 1235995209